Pricing Log in Create free account

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) vs Karyopharm Therapeutics Inc. (KPTI)

Biodexa Pharmaceuticals PLC Unsponsored ADR and Karyopharm Therapeutics Inc. are both Biotechnology companies. Biodexa Pharmaceuticals PLC Unsponsored ADR and Karyopharm Therapeutics Inc. are of similar size ($1.4M and $1.3M). Biodexa Pharmaceuticals PLC Unsponsored ADR grew revenue faster over the last twelve months: 60.2% against 6.81%. Karyopharm Therapeutics Inc. has the higher net margin (−153.3% vs −1,155.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Biodexa Pharmaceuticals PLC Unsponsored ADR leads on 9 and Karyopharm Therapeutics Inc. on 6.

Valuation

Metric BDRX KPTI Biotechnology median
P/E n/m n/m 10.60
P/S n/m 0.01 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.20 n/m 0.66
EV/Sales (2.81) 1.27 9.02
Earnings yield (102.95%) (25,680.00%) (32.88%)
Free cash flow yield 0.00% (4,526.16%) (23.13%)

Profitability

Metric BDRX KPTI Biotechnology median
Gross margin 0.00% 95.89% 68.51%
Operating margin 0.00% (56.17%) 0.00%
Net margin (1,155.70%) (153.28%) 0.00%
Free cash flow margin 0.00% (44.57%) 0.00%
Return on equity 0.00% 78.98% (51.96%)
Return on assets 0.00% (207.90%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BDRX KPTI Biotechnology median
Revenue growth (TTM) 60.22% 6.81% 6.76%
EPS growth (last fiscal year) 89.62% (28.07%) 29.88%
Revenue growth, 5-year CAGR (28.78%) 6.21% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BDRX KPTI Biotechnology median
Debt to equity 0.00 (0.76) 0.00
Current ratio 2.41 0.79 4.97
Net debt to EBITDA 1.00 (2.03) 1.01

Dividend

Metric BDRX KPTI Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BDRX KPTI Biotechnology median
Market cap 1.25m 1.36m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack